AMGEN INC. DL-,0001/ US0311621009 /
26/04/2024 08:25:20 | Chg. -1.8000 | Volume | Bid21:58:52 | Ask21:58:18 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
251.4000EUR | -0.71% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 135.31 bill.EUR | - | - |
GlobeNewswire
24/04
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
23/04
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
15/04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
15/04
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
08/04
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
08/04
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...
GlobeNewswire
05/04
CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US
GlobeNewswire
04/04
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
GlobeNewswire
03/04
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...
GlobeNewswire
25/03
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
25/03
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Director...
GlobeNewswire
20/03
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update